France Moves Forward

What happens when a country as central as France opens the door to medical cannabis?

After years of hesitation, the French government has officially announced its intention to legalize medical cannabis in a controlled and secure framework. This marks a turning point for one of Europe’s most influential nations—and a major step forward for patients across the continent.

For Cannerald, based just across the border in Switzerland, this evolution is both welcome and long-awaited. It validates the path we’ve been walking for years: placing quality, science, and safety at the core of everything we produce.

‍

What France is proposing

According to the report from Le Figaro, the French authorities are preparing a system that will:

Allow access to medical cannabis exclusively by prescription.
Involve a strictly regulated production and supply chain, overseen by the ANSM (France’s National Agency for Medicines).
Limit usage to specific therapeutic indications, including chronic pain, epilepsy, cancer-related symptoms, and palliative care.
Launch a national medical cannabis framework by 2025, building on the pilot program started in 2021.

This evolution is not about normalizing recreational use—it’s about recognizing the real medical needs of patients, and responding with professionalism and care.

‍

Cannerald’s role in this new chapter

As a Swiss-based certifiedMedical Cannabis producer, we’re proud to be part of a European movement that champions:

^{Controlled cultivation}
^{Pharmaceutical-grade standards}
^{Clear medical pathways for patients}

We stand ready to support the French market—as well as others in Europe—by providing safe, consistent, and high-quality cannabis-based therapies. We believe in a future where cannabis is no longer controversial, but simply a tool for healing.

‍